Open Access
HPV and CSC in HNSCC cisplatin resistance
Vishnu Modur1,K. Thomas Robbins1,Krishna Rao1,*
SIU School of Medicine, Springfield, IL, 62702, USA
DOI: 10.2741/E717 Volume 7 Issue 1, pp.66-76
Published: 01 January 2015
*Corresponding Author(s):  
Krishna Rao

Cisplatin (DNA intercalator), a standard chemotherapy drug often used to treat head and neck squamous cellular carcinoma (HNSCC) has very low response rates in recurrent disease of HNSCC, this is a major clinical problem today. However, a valuable window to look in to the underlying molecular aspects of a favorable and unfavorable cisplatin response is offered by a distinct disease entity in HNSCC – HPV+ OPSCC. It responds far more favorably to cisplatin than non-HPV driven HNSCC. Another intriguing aspect of head and neck cancer biology is the emergence of the CD44+ cancer stem cell - the tumor initiating population that in all likelihood is the root cause of therapeutic resistance. The critical question is, are there any differences between the CD44+ CSC population of an HPV+ OPSCC and a non-HPV HNSCC? In this regard, the inverse relation between EGFR levels and HPV status in OPSCC may be a common thread that connects the better response rates of HPV+ OPSCC with the contribution of CD44+ stem cells of HNSCC to chemoresistance.

Key words
HNSCC,Head And Neck Cancer,Cancer stem cells,Cisplatin,HPV,EGFR,CD44,Review
Share and Cite
Vishnu Modur, K. Thomas Robbins, Krishna Rao. HPV and CSC in HNSCC cisplatin resistance. Frontiers in Bioscience-Elite. 2015. 7(1); 66-76.